NasdaqGM - Delayed Quote • USD
Cognition Therapeutics, Inc. (CGTX)
At close: April 24 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -0.25 | -0.22 | -0.97 | -1.19 |
| Low Estimate | -0.26 | -0.28 | -1.34 | -1.83 |
| High Estimate | -0.23 | -0.15 | -0.62 | -0.59 |
| Year Ago EPS | -0.21 | -0.16 | -0.86 | -0.97 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.17 | -0.19 | -0.24 | -0.34 |
| EPS Actual | -0.21 | -0.16 | -0.22 | -0.27 |
| Difference | -0.04 | 0.03 | 0.02 | 0.07 |
| Surprise % | -23.50% | 15.80% | 8.30% | 20.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.25 | -0.22 | -0.97 | -1.19 |
| 7 Days Ago | -0.25 | -0.22 | -0.97 | -1.19 |
| 30 Days Ago | -0.29 | -0.3 | -1.1 | -1.31 |
| 60 Days Ago | -0.29 | -0.3 | -1.1 | -1.31 |
| 90 Days Ago | -0.29 | -0.3 | -1.1 | -1.31 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CGTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -19.00% | -- | -- | 1.50% |
| Next Qtr. | -37.50% | -- | -- | 11.40% |
| Current Year | -12.80% | -- | -- | 5.20% |
| Next Year | -22.70% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | B. Riley Securities: Buy to Buy | 3/28/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/27/2024 |
| Maintains | Ladenburg Thalmann: Buy to Buy | 8/14/2023 |
| Reiterates | Oppenheimer: Outperform | 5/9/2023 |
| Reiterates | Oppenheimer: Outperform | 3/24/2023 |
| Initiated | Cantor Fitzgerald: Overweight | 9/29/2022 |
Related Tickers
RNXT RenovoRx, Inc.
1.2130
+2.80%
ACOGF Alpha Cognition Inc.
0.4928
-0.44%
ACIU AC Immune SA
2.3700
-0.42%
INAB IN8bio, Inc.
1.0600
+1.92%
CUE Cue Biopharma, Inc.
1.4200
-5.33%
TFFP TFF Pharmaceuticals, Inc.
3.0100
-0.50%
ALRN Aileron Therapeutics, Inc.
4.9300
+3.79%
COYA Coya Therapeutics, Inc.
8.41
+4.86%
ALGS Aligos Therapeutics, Inc.
0.8290
+0.66%
ZURA Zura Bio Limited
3.3100
-4.89%